- Home
- INM vs SNN Comparison
INM vs SNN Comparison
Compare INM & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- SNN
- Stock Information
- Founded
- INM 1981
- SNN 1856
- Country
- INM Canada
- SNN United Kingdom
- Employees
- INM N/A
- SNN N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- SNN Industrial Specialties
- Sector
- INM Health Care
- SNN Health Care
- Exchange
- INM Nasdaq
- SNN Nasdaq
- Market Cap
- INM 4.3M
- SNN 13.2B
- IPO Year
- INM N/A
- SNN 1999
- Fundamental
- Price
- INM $2.33
- SNN $37.35
- Analyst Decision
- INM
- SNN Hold
- Analyst Count
- INM 0
- SNN 3
- Target Price
- INM N/A
- SNN $31.50
- AVG Volume (30 Days)
- INM 44.9K
- SNN 642.7K
- Earning Date
- INM 11-13-2025
- SNN 10-30-2025
- Dividend Yield
- INM N/A
- SNN 1.96%
- EPS Growth
- INM N/A
- SNN 59.91
- EPS
- INM N/A
- SNN 0.56
- Revenue
- INM $4,920,990.00
- SNN $5,944,000,000.00
- Revenue This Year
- INM N/A
- SNN $7.75
- Revenue Next Year
- INM N/A
- SNN $5.37
- P/E Ratio
- INM N/A
- SNN $67.04
- Revenue Growth
- INM N/A
- SNN 5.35
- 52 Week Low
- INM $1.72
- SNN $23.69
- 52 Week High
- INM $8.27
- SNN $38.79
- Technical
- Relative Strength Index (RSI)
- INM 54.08
- SNN 53.86
- Support Level
- INM $2.03
- SNN $37.92
- Resistance Level
- INM $2.28
- SNN $38.59
- Average True Range (ATR)
- INM 0.08
- SNN 0.33
- MACD
- INM -0.09
- SNN -2.27
- Stochastic Oscillator
- INM 98.73
- SNN 96.31
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.